These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 12209961)

  • 1. Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug.
    Ortu G; Ben-David I; Rozen Y; Freedman NM; Chisin R; Levitzki A; Mishani E
    Int J Cancer; 2002 Oct; 101(4):360-70. PubMed ID: 12209961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon: [11C]acryloyl chloride.
    Ben-David I; Rozen Y; Ortu G; Mishani E
    Appl Radiat Isot; 2003 Feb; 58(2):209-17. PubMed ID: 12573320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors.
    Mishani E; Abourbeh G; Rozen Y; Jacobson O; Laky D; Ben David I; Levitzki A; Shaul M
    Nucl Med Biol; 2004 May; 31(4):469-76. PubMed ID: 15093817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts.
    Vincent PW; Bridges AJ; Dykes DJ; Fry DW; Leopold WR; Patmore SJ; Roberts BJ; Rose S; Sherwood V; Zhou H; Elliott WL
    Cancer Chemother Pharmacol; 2000; 45(3):231-8. PubMed ID: 10663641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors.
    Mishani E; Abourbeh G; Jacobson O; Dissoki S; Ben Daniel R; Rozen Y; Shaul M; Levitzki A
    J Med Chem; 2005 Aug; 48(16):5337-48. PubMed ID: 16078851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of radioiodinated phenoxyquinazoline and benzylaminoquinazoline derivatives as new EGF receptor tyrosine kinase imaging ligands for tumor diagnosis using SPECT.
    Hirata M; Kanai Y; Naka S; Matsumuro K; Kagawa S; Yoshimoto M; Ohmomo Y
    Ann Nucl Med; 2012 Jun; 26(5):381-9. PubMed ID: 22354330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
    Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
    J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioiodination of new EGFR inhibitors as potential SPECT agents for molecular imaging of breast cancer.
    Fernandes C; Oliveira C; Gano L; Bourkoula A; Pirmettis I; Santos I
    Bioorg Med Chem; 2007 Jun; 15(12):3974-80. PubMed ID: 17449254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors.
    Abourbeh G; Dissoki S; Jacobson O; Litchi A; Ben Daniel R; Laki D; Levitzki A; Mishani E
    Nucl Med Biol; 2007 Jan; 34(1):55-70. PubMed ID: 17210462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer.
    Shaul M; Abourbeh G; Jacobson O; Rozen Y; Laky D; Levitzki A; Mishani E
    Bioorg Med Chem; 2004 Jul; 12(13):3421-9. PubMed ID: 15186828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
    J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of radioiodinated quinazoline derivative as a new ligand for EGF receptor tyrosine kinase activity using SPECT.
    Hirata M; Kanai Y; Naka S; Matsumuro K; Kagawa S; Yoshimoto M; Ohmomo Y
    Ann Nucl Med; 2011 Feb; 25(2):117-24. PubMed ID: 21058048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of epidermal growth factor receptor targeting probe [11C]PD153035: impact on biodistribution and tumor uptake in rats.
    Samén E; Arnberg F; Lu L; Olofsson MH; Tegnebratt T; Thorell JO; Holmin S; Stone-Elander S
    J Nucl Med; 2013 Oct; 54(10):1804-11. PubMed ID: 24003078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiohalogenated 4-anilinoquinazoline-based EGFR-TK inhibitors as potential cancer imaging agents.
    Neto C; Fernandes C; Oliveira MC; Gano L; Mendes F; Kniess T; Santos I
    Nucl Med Biol; 2012 Feb; 39(2):247-60. PubMed ID: 22079040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
    Smaill JB; Rewcastle GW; Loo JA; Greis KD; Chan OH; Reyner EL; Lipka E; Showalter HD; Vincent PW; Elliott WL; Denny WA
    J Med Chem; 2000 Apr; 43(7):1380-97. PubMed ID: 10753475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel multivalent (99m)Tc-labeled EG2-C4bpα antibody for targeting the epidermal growth factor receptor in tumor xenografts.
    Li C; Zhang Y; Wang L; Feng H; Xia X; Ma J; Yuan H; Gao B; Lan X
    Nucl Med Biol; 2015 Jun; 42(6):547-54. PubMed ID: 25779037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.
    Lichtner RB; Menrad A; Sommer A; Klar U; Schneider MR
    Cancer Res; 2001 Aug; 61(15):5790-5. PubMed ID: 11479217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
    Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
    J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase.
    Bonasera TA; Ortu G; Rozen Y; Krais R; Freedman NM; Chisin R; Gazit A; Levitzki A; Mishani E
    Nucl Med Biol; 2001 May; 28(4):359-74. PubMed ID: 11395308
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.